touchCARDIO touchCARDIO
Arrhythmia, Devices
Read Time: 2 mins

22/Management of patients following ICD therapy: The importance of a multifaceted approach

Copy Link
Published Online: Oct 8th 2020 European Journal of Arrhythmia & Electrophysiology. 2023;9(Suppl. 1):abstr22
Authors: Miss Selvarajah (Presenting Author) – King’s College Hospital, London, UK; Mrs Khan – King’s College Hospital, London, UK; Mr Jahagirdar – King’s College Hospital, London, UK; Dr Cannata – King’s College Hospital, London, UK; Dr Mukherjee – King’s College Hospital, London, UK; Dr Bromage – King’s College Hospital, London, UK; Dr McDonagh – King’s College Hospital, London, UK; Dr Murgatroyd – King’s College Hospital, London, UK; Dr Scott – King’s College Hospital, London, UK
Quick Links:
Article
Article Information
Article:

Background: In patients presenting following a first implantable cardioverter defibrillator (ICD) therapy, the risk of a subsequent ICD therapy is elevated. The most effective way to treat these patients is unknown. We hypothesised that in patients presenting following their first ICD therapy, a multifaceted approach combining treatment strategies would lead to a reduction in the risk of subsequent therapy compared to using single strategies alone.

Methods: We included consecutive patients undergoing ICD implantation between 2009 and 2019 at King’s College Hospital, London who had experienced their first ICD therapy. We assessed the use of 7 specific treatment strategies (starting/increasing betablockers, starting/increasing non-betablocker prognostic heart failure medications, starting/increasing antiarrhythmic drugs, ICD reprogramming, ablation, ICD lead upgrade/revision and coronary revascularization) introduced after the first ICD therapy. We evaluated the association between the introduction of these treatment strategies and the risk of a subsequent ICD therapy during follow-up.

Results: We assessed 1,003 new ICD recipients; during a mean follow-up of 1,519 ± 1,055 days, 267 experienced a first ICD therapy (212 appropriate and 55 inappropriate) and were included in the analysis.

During a mean follow-up of 1,126 ± 1,103 days following the first appropriate therapy, 113/212 patients had a subsequent appropriate ICD therapy, of which 66 had an appropriate shock. Compared to patients where 0/7 treatment strategies were used (n=59), patients where 1/7 treatment strategy was introduced (n=80) had a 42% lower risk of a subsequent appropriate therapy and ³2/7 treatment strategies (n=73) was associated with a 57% reduction (p=0.002).

During a mean follow-up of 1,340 ± 1,305 days following a first inappropriate therapy, 18/55 patients had a subsequent inappropriate ICD therapy, of which 15 had an inappropriate shock. Compared to patients where 0/7 treatment strategies were used (n=8), patients where 1 treatment strategy was introduced (n=22) had an 86% lower risk of a subsequent inappropriate therapy and ³2/7 treatment strategies (n=25) was associated with a 94% reduction in the risk of a subsequent inappropriate therapy (p<0.001).

These associations remained significant when adjusted for baseline variables.

Conclusions: For both appropriate and inappropriate therapy, the risk of a subsequent ICD therapy is significantly elevated following the first therapy. A multifaceted approach combining treatment strategies may be more effective than the use of individual strategies alone to prevent subsequent therapy in patients presenting following a first ICD therapy. 

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72